Prevalence of Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian cancer patients from Brazil reveals differences among Latin American populations

Cancer Genetics

Volumn 209, Issue 9, 2016, Pages 417-422

  Alemar, Bárbara ^a,b   Herzog, Josef ^c   Brinckmann Oliveira Netto, Cristina ^b   Artigalás, Osvaldo ^d   Schwartz, Ida Vanessa D ^a,b   Matzenbacher Bittar, Camila ^a   Ashton Prolla, Patricia ^a,b   Weitzel, Jeffrey N ^c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c Division of Clinical Cancer Genetics   (United States)

^d HOSPITAL MOINHOS DE VENTO   (Brazil)

Author keywords

BRCA1; BRCA2; Hereditary breast and ovarian cancer

Indexed keywords

ADULT; AGED; ARTICLE; BRAZIL; CANCER PATIENT; CANCER SCREENING; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FAMILY HISTORY; FEMALE; GENE SEQUENCE; GENOTYPE; GERMLINE MUTATION; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATIONAL ANALYSIS; POPULATION GENETICS; POPULATION RESEARCH; POPULATION STRUCTURE; PREVALENCE; PRIORITY JOURNAL; SOUTH AND CENTRAL AMERICA; TUMOR SUPPRESSOR GENE; BREAST TUMOR; GENETICS; MIDDLE AGED; MUTATION; OVARY TUMOR; YOUNG ADULT;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; HISPANIC AMERICANS; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; YOUNG ADULT;

EID: 84992202237     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2016.06.008     Document Type: Article

References (45)

1. 1 Ferlay, J., Soerjomataram, I., Dikshit, R., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359–E386.
2. 2 Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J Clin 66 (2016), 7–30.
3. 3 Lee, B.L., Liedke, P.E., Barrios, C.H., et al. Breast cancer in Brazil: present status and future goals. Lancet Oncol 13 (2012), e95–e102.
4. 4 Estimativa 2016: Incidência de Câncer no Brasil (Estimate/2016—Cancer Incidence in Brazil), 2015, Instituto Nacional de Câncer José Alencar Gomes da Silva, Coordenação de Prevenção e Vigilância, Rio de Janeiro.
5. 5 Lindor, N.M., McMaster, M.L., Lindor, C.J., et al. Concise handbook of familial cancer susceptibility syndromes—second edition. J Natl Cancer Inst Monogr, 2008, 1–93.
6. 6 Claus, E.B., Schildkraut, J.M., Thompson, W.D., et al. The genetic attributable risk of breast and ovarian cancer. Cancer 77 (1996), 2318–2324.
7. 7 Rebbeck, T.R., Mitra, N., Wan, F., et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313 (2015), 1347–1361.
8. 8 Castro, E., Goh, C., Olmos, D., et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 31 (2013), 1748–1757.
9. 9 Narod, S.A., Neuhausen, S., Vichodez, G., et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 99 (2008), 371–374.
10. 10 Hernández, J.E., Llacuachaqui, M., Palacio, G.V., et al. Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Medellín, Colombia. Hered Cancer Clin Pract, 12, 2014, 11.
11. 11 Rodríguez, A.O., Llacuachaqui, M., Pardo, G.G., et al. BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia. Gynecol Oncol 124 (2012), 236–243.
12. 12 Hall, M.J., Reid, J.E., Burbidge, L.A., et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 115 (2009), 2222–2233.
13. 13 Weitzel, J.N., Clague, J., Martir-Negron, A., et al. Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network. J Clin Oncol 31 (2013), 210–216.
14. 14 Weitzel, J.N., Blazer, K.R., MacDonald, D.J., et al. Genetics, genomics and cancer risk assessment: state of the art and future directions in the era of personalized medicine. CA Cancer J Clin 61 (2011), 327–359.
15. 15 Blazer, K.R., MacDonald, D.J., Culver, J.O., et al. Personalized cancer genetics training for personalized medicine: improving community-based healthcare through a genetically literate workforce. Genet Med 13 (2011), 832–840.
16. 16 Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol 14 (1996), 1730–1736 discussion 1737-1740.
17. 17 Robson, M.E., Bradbury, A.R., Arun, B., et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 33 (2015), 3660–3667.
18. 18 Frank, T.S., Deffenbaugh, A.M., Reid, J.E., et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20 (2002), 1480–1490.
19. 19 Antoniou, A.C., Hardy, R., Walker, L., et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet 45 (2008), 425–431.
20. 20 Villarreal-Garza, C., Alvarez-Gómez, R.M., Pérez-Plasencia, C., et al. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico. Cancer 121 (2015), 372–378.
21. 21 Dufloth, R.M., Carvalho, S., Heinrich, J.K., et al. Analysis of BRCA1 and BRCA2 mutations in Brazilian breast cancer patients with positive family history. Sao Paulo Med J 123 (2005), 192–197.
22. 22 Gomes, M.C., Costa, M.M., Borojevic, R., et al. Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res Treat 103 (2007), 349–353.
23. 23 Esteves, V.F., Thuler, L.C., Amêndola, L.C., et al. Prevalence of BRCA1 and BRCA2 gene mutations in families with medium and high risk of breast and ovarian cancer in Brazil. Braz J Med Biol Res 42 (2009), 453–457.
24. 24 Carraro, D.M., Koike Folgueira, M.A., Garcia Lisboa, B.C., et al. Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil. PLoS ONE, 8, 2013 e57581.
25. 25 Silva, F.C., Lisboa, B.C., Figueiredo, M.C., et al. Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients. BMC Med Genet, 15, 2014, 55.
26. 26 Felix, G.E., Abe-Sandes, C., Machado-Lopes, T.M., et al. Germline mutations in BRCA1, BRCA1, CHEK2 and TP53 in patients at high-risk for HBOC: characterizing a Northeast Brazilian Population. Hum Genome Var, 1, 2014, 14012.
27. 27 Abugattas, J., Llacuachaqui, M., Allende, Y.S., et al. Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru. Clin Genet 88 (2015), 371–375.
28. 28 Vaca-Paniagua, F., Alvarez-Gomez, R.M., Fragoso-Ontiveros, V., et al. Full-exon pyrosequencing screening of BRCA germline mutations in Mexican women with inherited breast and ovarian cancer. PLoS ONE, 7, 2012 e37432.
29. 29 Solano, A.R., Aceto, G.M., Delettieres, D., et al. BRCA1 and BRCA2 analysis of Argentinean breast/ovarian cancer patients selected for age and family history highlights a role for novel mutations of putative south-American origin. Springerplus, 1, 2012, 20.
30. 30 Torres, D., Rashid, M.U., Gil, F., et al. High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. Breast Cancer Res Treat 103 (2007), 225–232.
31. 31 Gallardo, M., Silva, A., Rubio, L., et al. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations. Breast Cancer Res Treat 95 (2006), 81–87.
32. 32 Gonzalez-Hormazabal, P., Gutierrez-Enriquez, S., Gaete, D., et al. Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families. Breast Cancer Res Treat 126 (2011), 705–716.
33. 33 Delgado, L., Fernández, G., Grotiuz, G., et al. BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants. Breast Cancer Res Treat 128 (2011), 211–218.
34. 34 Abeliovich, D., Kaduri, L., Lerer, I., et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60 (1997), 505–514.
35. 35 Roa, B.B., Boyd, A.A., Volcik, K., et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14 (1996), 185–187.
36. 36 Hamel, N., Feng, B.J., Foretova, L., et al. On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. Eur J Hum Genet 19 (2011), 300–306.
37. 37 Lourenço, J.J., Vargas, F.R., Bines, J., et al. BRCA1 mutations in Brazilian patients. Genet Mol Biol, 2004, 500–504.
38. 38 da Costa, E.C., Vargas, F.R., Moreira, A.S., et al. Founder effect of the BRCA1 5382insC mutation in Brazilian patients with hereditary breast ovary cancer syndrome. Cancer Genet Cytogenet 184 (2008), 62–66.
39. 39 Machado, P.M., Brandão, R.D., Cavaco, B.M., et al. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol 25 (2007), 2027–2034.
40. 40 Díez, O., Osorio, A., Durán, M., et al. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat 22 (2003), 301–312.
41. 41 Neuhausen, S.L., Godwin, A.K., Gershoni-Baruch, R., et al. Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet 62 (1998), 1381–1388.
42. 42 Mohamad, H.B., Apffelstaedt, J.P., Counseling for male BRCA mutation carriers: a review. Breast 17 (2008), 441–450.
43. 43 Weiss, J.R., Moysich, K.B., Swede, H., Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev 14 (2005), 20–26.
44. 44 Friedman, L.S., Gayther, S.A., Kurosaki, T., et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 60 (1997), 313–319.
45. 45 Thorlacius, S., Sigurdsson, S., Bjarnadottir, H., et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 60 (1997), 1079–1084.